EULAR 26 Hears of Treatment Advances in Lupus

Why It Matters

These data could expand the limited SLE therapeutic arsenal, offering mechanisms that target autoantibody recycling, CD40L signaling, and innate immune pathways, potentially improving outcomes and reducing steroid dependence.

Key Takeaways

• Nipocalimab met primary endpoint with 53.5% SRI‑4 response.
• Dapirolizumab pegol lowered flare rates and steroid use.
• Enpatoran achieved 75% skin improvement at high dose.
• Phase‑3 trials for all three agents slated for 2028 readouts.

Pulse Analysis

Systemic lupus erythematosus affects 3‑5 million people worldwide and remains one of the most challenging autoimmune diseases to manage. Current standards rely heavily on corticosteroids and a handful of biologics such as belimumab, anifrolumab, and obinutuzumab, which only modestly control disease activity and often leave patients with persistent organ damage. The European Alliance of Associations for Rheumatology (EULAR) meeting in London highlighted a new wave of targeted agents that aim to intervene earlier in the pathogenic cascade, offering hope for more durable remission and reduced steroid exposure.

Johnson & Johnson’s nipocalimab, the first FcRn inhibitor tested in lupus, demonstrated a statistically significant SRI‑4 response of 53.5 % at 24 weeks and maintained efficacy through one year, confirming the therapeutic promise of reducing pathogenic IgG recycling. Biogen and UCB’s dapirolizumab pegol, which blocks CD40L signaling, not only improved LLDAS rates to 40.9 % but also cut the frequency of moderate‑to‑severe flares and allowed patients to taper steroids. Merck’s enpatoran, a TLR 7/8 antagonist, produced striking cutaneous improvements, with three‑quarters of high‑dose participants achieving a 50‑70 % reduction in CLASI‑70 scores after 48 weeks.

If the ongoing phase‑3 programs—GARDENIA, PHOENYCS FLY, and the enpatoran pivotal trials—confirm these early signals, the lupus market could see its first class of therapies that address distinct immunologic pathways, diversifying treatment algorithms and potentially commanding premium pricing. Payers will likely scrutinize long‑term safety and steroid‑sparing benefits, while rheumatologists may adopt a more personalized approach based on autoantibody profiles and organ involvement. Ultimately, these advances could shift the therapeutic landscape toward earlier disease control, lower cumulative organ damage, and improved quality of life for millions of patients.